tbuckley/cabot-search huggingface dataset:
A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
Authors: D. J. Schwartzentruber, D. Lawson, J. Richards, R. M. Conry, D. Miller, J. Triesman, F. Gailani, L. B. Riley, D. Vena, P. Hwu
Journal: Journal of Clinical Oncology (2009)

CRA9011 Background: In a phase II study, 13 (42%) of 31 patients with metastatic melanoma receiving high-dose (HD) IL-2 plus gp100:209–217(210M) peptide experienced objective responses (S.A. Rosenberg, et al, Nature Medicine 4: 321–327, 1998). Other studies showed a lower response rate (RR) but no randomized studies have been done. Methods: A prospective randomized phase III trial was conducted at 21 centers with 185 patients. Eligibility: stage IV or locally advanced stage III cutaneous melanoma, HLA A0201, no brain metastases, eligible for HD IL-2, and no previous HD IL-2 or gp100:209–217(210M). Arm 1 received HD IL-2 alone (720,000 IU/kg/dose) and Arm 2 gp100:209–217(210M) peptide + Montanide ISA followed by HD IL-2. The primary objective was clinical response. Secondary objectives were toxicity, disease free/progression free survival, immunologic response and quality of life. Central HLA typing, pathology review, and blinded response assessment were done at the NIH. Central data monitoring was done by The EMMES Corp. and a Data Safety Monitoring Board. Results: Numbers of patients enrolled, treated, and evaluable for response in Arm 1 were 94, 93, and 93 respectively; in Arm 2 91, 86, and 86. Toxicities were consistent with HD IL-2 ± vaccine. Investigator assessed RR showed significant improvement in overall RR for Arm 2=22.1% vs 9.7% (P=0.0223, Chi-Square) and progression free survival (PFS) in favor of Arm 2=2.9 months (1.7–4.5) vs 1.6 (1.5–1.8) (P=0.0101). Median overall survival favors Arm 2=17.6 months (11.8–26.6) vs 12.8 (8.7–16.3) (P=0.0964). Blinded response review is ongoing. Conclusions: RR and PFS were superior with peptide vaccine and HD IL-2 compared to HD IL-2 alone. This represents the first evidence of clinical benefit of vaccination in patients with melanoma. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis NIH, Novartis
Local Anesthetics
Authors: Frank Perlroth
Journal: JAMA (1970)

<h3>To the Editor:—</h3> Regarding "Allergy to Local Anesthetics" (<b>207:</b>356, 1969) and subsequent correspondence in LETTERS, I have found a useful alternative in those situations in which there is a history of "caine allergy." When the need for prompt therapy exists, injectable diphenhydramine hydrochloride (Benadryl) produces sufficient local anesthesia to permit most small surgical procedures, aspirations, and local infiltrations. While this is noted in major texts of pharmacology, it is not known to the practicing physicians generally.
Patients' and Families' Preferences for Medical Intensive Care
Authors: Marion Danis
Journal: JAMA (1988)

Medical ethics suggest that life-sustaining treatment decisions should be made with consideration for patients' preferences and quality of life. Patients were interviewed who were at least 55 years old and had experienced medical intensive care at a university hospital during a one-year period to determine their preferences regarding intensive care; family members were interviewed if the patient had died (n = 160). Seventy percent of patients and families were 100% willing to undergo intensive care again to achieve even one month of survival; 8% were completely unwilling to undergo intensive care to achieve any prolongation of survival. Preferences were poorly correlated with functional status or quality of life and were not altered by life expectancy for 82% of respondents. Age, severity of critical illness, length of stay, and charges for intensive care did not influence willingness to undergo intensive care. These data suggest that personal preferences may conflict with any health policy that limits the allocation of intensive care based on age, function, or quality of life. (<i>JAMA</i>1988;260:797-802)
Influence of Sleep on Respiratory Function in Emphysema
Authors: Robert D. Ballard, C. Wyant Clover, Benedict Y. Suh
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

To assess the influence of sleep on respiratory function, five patients with chronic obstructive pulmonary disease (COPD) with laboratory evidence of emphysema were monitored during sleep in a horizontal body plethysmograph. Neither lung volume nor lower airway resistance (Rla) changed in association with sleep. Upper airway resistance (Rua) increased during sleep and was highest during rapid eye movement (REM) sleep (Rua = 5.9 ± 1.1, 9.6 ± 2.1, 11.2 ± 1.5, and 15.6 ± 4.1 cm H2O/L/s during wakefulness, Stages 2, 3–4, and REM, respectively, p < 0.05). Tidal volume (Vt) decreased during sleep, resulting in a sleep-associated decrement in minute ventilation (i = 8.69 ± 0.46, 7.64 ± 0.65, 7.08 ± 0.70, and 5.62 ± 0.47 L during wakefulness, Stages 2, 3–4, and REM, respectively, p < 0.05). Respiratory neuromuscular output was also reduced during sleep (esophageal occlusion pressure [P0.1] = 2.69 ± 0.39, 2.02 ± 0.27, 1.90 ± 0.27, and 1.63 ± 0.25 cm H2O during wakefulness, Stages 2, 3–4, and REM, respectively, p = 0.005). We conclude that in patients with emphysema (1) sleep does not alter lung volume or increase lower airway resistance, (2) sleep is associated with a decrease in Vt and i, and (3) sleep is associated with an increase in Rua and a reduction in P0.1 that may contribute to the sleep-associated decrease in i.
Salvage of the ischemic limb. Hemodynamic changes during surgery
Authors: V. M. Bernhard
Journal: JAMA (1968)

Limb salvage was achieved in 30 (77%) of 39 patients subjected to bypass surgery for end stage ischemia. Pressure gradients were reduced to zero after aortofemoral bypass; however, a small residual gradient was usually present after femoral-popliteal vein graft. Arterial flows were markedly increased at all levels following bypass. There was no difference in postoperative flow between patients whose limbs were salvaged and those with lesser degrees of ischemia. Average flow per extremity was 270 ml/min after aorto-iliac bypass and 100 ml/min after femoral-popliteal bypass. Local intra-arterial infection of papaverine hydrochloride increased flow to 170 ml/min following femoral-popliteal bypass. Ultimate flow potential of the limb may be estimated by this test. Failure to increase flow with papaverine suggests technical error.
Ondine Undone
Authors: Eugene Nattie
Journal: New England Journal of Medicine (2015)

Imagine having to remember to breathe, as in the myth of Ondine, who was cursed to think consciously of breathing even in sleep. The term "Ondine's curse" has been applied to the congenital central hypoventilation syndrome (CCHS), a condition in which children hypoventilate and retain carbon dioxide (especially in sleep), have prominent apneas, and have a severely diminished carbon dioxide chemoreflex (the increase in breathing in response to elevated carbon dioxide levels). The cause of CCHS is a mutation in PHOX2B that affects a single amino acid in the PHOX2B protein. When this mutation is introduced into a mouse, much . . .
Lectures on Pathology Delivered at the London Hospital.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights from this issue
Authors: The Triumvirate
Journal: Thorax (2020)

The TriumvirateThis month sees the start of a New Year, with 2021 brim full of optimism from the development of a SARS-CoV-2 vaccine and the inauguration of a new US president, with both offering a possibly for the return to some degree of normality.With this issue of Airwaves we look back on the recent election and forward to the next year with renewed optimism.
Epithelial ovarian cancer and combination oral contraceptives
Authors: L. Rosenberg
Journal: JAMA (1982)

The risk of epithelial ovarian cancer in relation to the use of combination oral contraceptives was evaluated in a case-control study of women younger than 60 years. Combination oral contraceptives were used by 35 (26%) of 136 cases and 187 (35%) of 539 controls. The relative risk estimate for combination oral contraceptive use was 0.6 (95% confidence interval, 0.4 to 0.9). The reduction in risk appeared to persist for as long as ten years after use had ceased and to be greater for longer durations of use, but these results were not statistically significant. The findings were not explained by parity or by other identified potential confounding factors. The results suggest that the use of combination oral contraceptives protects against epithelial ovarian cancer. (<i>JAMA</i>1982;247:3210-3212)
Spontaneous Calcific Embolization Associated with Calcific Aortic Stenosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Importation of Foreign Natural Mineral Waters.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
WITHDRAWN
Authors: I Bot, ; Kritikou, ; Van Der Heijden, ; Swart, ; Van Duijn, ; Slutter, ; Wezel, H Smeets, ; Maffia, ; Kuiper, A Gombozhapova, ; Rogovskaya, ; Rebenkova, ; Kzhyshkowska, ; Ryabov
Journal: Cardiovascular Research (2018)

Background: Atherosclerosis development is enhanced by both local and systemic immune responses and mast cells have been shown to accumulate inside atherosclerotic plaques where these cells can degranulate and contribute to disease progression.Our research focused on pathways via which mast cells can elicit their atherogenic effects, such as by shaping the adaptive immune reaction through a direct interaction with CD4þ T-cells.In this study, we thus aimed to analyze the interplay between mast cells and CD4þ T-cells in atherosclerosis.Methods: and Results: In LDLr-/-mice fed a Western-type diet (WTD), the MHC-IIþ/ FceRIaþCD117þ mast cell population in the peritoneum increased significantly (0 wk-WTD:30.461.7%; 4 wk-WTD:52.565.9%,P¼0.01).To examine the efficacy of the MHC-II expressing mast cells in vivo, we injected i/p the Ea-peptide (1mg/mL), which is specifically presented by MHC-II molecules.After 24 hours, we detected Ea-peptide fragments on the peritoneal mast cell surface (PBS:2.360.2%;Ea:7.461.7%;P¼0.02).Interestingly, we also observed that bone marrow derived mast cells (BMMCs) treated in vitro with 10% serum of LDLr-/-mice fed a WTD diet for 4 weeks, showed enhanced MHC-II expression on their surface (chow-MCs: 3.160.3%vs WTD-MCs: 10.2560.1%,P<0.0001).To further investigate the effect of hyperlipidemia in the antigen presentation capacity of mast cells to CD4þ T-cells, we made use of the Ovalbumin presentation system by which CD4þ T-cells from genetically modified OT-II mice can specifically respond to OVA-peptide (OVAp) fragments.Therefore, we co-cultured OVAp-pretreated (10lm/mL) BMMCs under either chow or WTD serum conditions, with OT-II CD4þ T-cells, previously activated by aCD3/aCD28.The proliferation rate of CD4þ T-cells was markedly increased in the WTD condition as measured by [3H]-Thymidine incorporation, (chow-MC: 903362222 dpm compared to WTD-MC: 2533262889 dpm, P<0.0001).Conversely, the aortic CD4þ content of mast cell deficient mice on WTD, showed a reduction in ki67þ/CD4þ proliferation (apoE-/-: 30.965.2% vs apoE/KitW-sh/W-sh: 13.161.2%;P¼0.006) with a pronounced decline in the number of TH1 T-betþ/CD4þ T-cells (apoE-/-:148.4624.5 cells; apoE/KitW-sh/W-sh:45.1616.4cells, P¼0.004).Of clinical relevance, upon examination of 20 human plaques obtained by endarterectomy surgery, we observed that 18.564.4% of human mast cells express HLA-DR (the human equivalent of MHC-II) suggesting that mast cells may be capable of antigen presentation inside the human atherosclerotic plaque. Conclusion:We have increasing evidence that mast cells may function as non-classical antigen presenting cells in atherosclerosis, possibly by influencing the pro-atherogenic TH1 cells inside the plaque microenvironment.Further studies on the role of mast cells as modulators of adaptive immunity may reveal novel means to intercept atherosclerosis development.
Synopsis of a Course of Lectures on the Anatomy, Physiology and Histo-Chemistry of the Nervous System.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Alendronate Improves Osteoporosis in Elderly Women Living in Long-Term Care Facilities
Journal: Annals of Internal Medicine (2002)

Summaries for Patients21 May 2002Alendronate Improves Osteoporosis in Elderly Women Living in Long-Term Care FacilitiesSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-10-200205210-00004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?As women get older, their bones become more fragile (a condition called osteoporosis). As a result, the risk of fracture increases. Up to 86% of female nursing home residents have osteoporosis. Alendronate is a medication used to treat osteoporosis. Many studies have shown that treatment of osteoporosis with alendronate in younger women improves bone density and prevents fractures. No one knows if elderly women with osteoporosis can be treated effectively.Why did the researchers do this particular study?To find out if elderly women living in long-term care ... Author, Article, and Disclosure InformationThe summary below is from the full report titled “Alendronate Improves Bone Mineral Density in Elderly Women with Osteoporosis Residing in Long-Term Care Facilities. A Randomized, Double-Blind, Placebo- Controlled Trial.” It is in the 21 May 2002 issue of Annals of Internal Medicine (volume 136, pages 742-746). The authors are SL Greenspan, DL Schneider, MR McClung, PD Miller, TJ Schnitzer, R Bonin, ME Smith, P DeLucca, GJ Gormley, and ME Melton.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians–American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAlendronate Improves Bone Mineral Density in Elderly Women with Osteoporosis Residing in Long-Term Care Facilities Susan L. Greenspan , Diane L. Schneider , Michael R. McClung , Paul D. Miller , Thomas J. Schnitzer , Randi Bonin , Mary Elizabeth Smith , Paul DeLucca , Glenn J. Gormley , and Mary E. Melton Metrics 21 May 2002Volume 136, Issue 10Page: I-54KeywordsBoneBone densityBone mineral densityCalciumDietElderlyHematologic testsLong-term careNursing homesOsteoporosis ePublished: 21 May 2002 Issue Published: 21 May 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
AN ARRAIGNMENT OF THE ARMY MEDICAL DEPARTMENT.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Vivo Assessment Of Neurotransmitter Biochemistry In Humans
Authors: J. Barrio
Journal: The Annual Review of Pharmacology and Toxicology (1988)

Over the past two decades, deadly coronaviruses, with the most recent being the severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) 2019 pandemic, have majorly challenged public health. The path for virus invasion into humans and other ...Read More